GlaxoSmithKline Pakistan Limited Stock

Equities

GLAXO

PK0001301016

Pharmaceuticals

End-of-day quote Pakistan S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
100.4 PKR +2.43% Intraday chart for GlaxoSmithKline Pakistan Limited +9.73% +20.98%
Sales 2022 41.84B 150M Sales 2023 49.66B 178M Capitalization 26.43B 94.96M
Net income 2022 2.46B 8.85M Net income 2023 534M 1.92M EV / Sales 2022 0.56 x
Net cash position 2022 4.41B 15.84M Net cash position 2023 2.89B 10.37M EV / Sales 2023 0.47 x
P/E ratio 2022
11.3 x
P/E ratio 2023
49.5 x
Employees 1,700
Yield 2022 *
-
Yield 2023
-
Free-Float 14.14%
More Fundamentals * Assessed data
Dynamic Chart
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Glaxosmithkline Pakistan Limited Announces Change of Company Secretary CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GlaxoSmithKline Pakistan Limited Announces Board Changes CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Glaxosmithkline Pakistan Limited Appoints Simon Forster as Director CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Glaxo Smith Kline Pakistan Limited Appoints Lai Kuen Goh as Director CI
GlaxoSmithKline Pakistan Limited Announces Board Changes CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
More news
1 day+2.43%
1 week+9.73%
Current month+18.37%
1 month+20.62%
3 months+26.11%
6 months+30.39%
Current year+20.98%
More quotes
1 week
90.00
Extreme 90
104.00
1 month
81.10
Extreme 81.1
104.00
Current year
77.00
Extreme 77
104.00
1 year
68.00
Extreme 68
104.00
3 years
68.00
Extreme 68
173.50
5 years
68.00
Extreme 68
203.80
10 years
68.00
Extreme 68
274.47
More quotes
Managers TitleAgeSince
Chief Executive Officer - 20-02-29
Director of Finance/CFO - 21-05-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 70 20-04-01
Director/Board Member - 18-12-04
Chief Executive Officer - 20-02-29
More insiders
Date Price Change Volume
24-04-26 100.4 +2.43% 280,000
24-04-25 98.02 +0.69% 260,500
24-04-24 97.35 -1.56% 118,000
24-04-23 98.89 +0.54% 581,500
24-04-22 98.36 +7.50% 308,000

End-of-day quote Pakistan S.E., April 25, 2024

More quotes
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, including but not limited to psoriasis, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
More about the company